Thomas F. Gajewski

55.2k total citations · 22 hit papers
321 papers, 36.1k citations indexed

About

Thomas F. Gajewski is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Thomas F. Gajewski has authored 321 papers receiving a total of 36.1k indexed citations (citations by other indexed papers that have themselves been cited), including 208 papers in Oncology, 192 papers in Immunology and 101 papers in Molecular Biology. Recurrent topics in Thomas F. Gajewski's work include Cancer Immunotherapy and Biomarkers (127 papers), Immunotherapy and Immune Responses (115 papers) and CAR-T cell therapy research (105 papers). Thomas F. Gajewski is often cited by papers focused on Cancer Immunotherapy and Biomarkers (127 papers), Immunotherapy and Immune Responses (115 papers) and CAR-T cell therapy research (105 papers). Thomas F. Gajewski collaborates with scholars based in United States, Australia and Switzerland. Thomas F. Gajewski's co-authors include Stefani Spranger, Yuanyuan Zha, Maria‐Luisa Alegre, Leticia Corrales, Jason J. Luke, F W Fitch, Jason B. Williams, Vyara Matson, Yuru Meng and Brendan Horton and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Thomas F. Gajewski

317 papers receiving 35.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy

2015 2.8k citations Ayelet Sivan, Leticia Corrales et al. Science profile →
The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

2018 2.1k citations Jessica Fessler, Riyue Bao et al. Science profile →
STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors

2014 1.5k citations Thomas F. Gajewski et al. profile →
STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

2014 1.4k citations Mercedes B. Fuertes, Stefani Spranger et al. profile →
Up-Regulation of PD-L1, IDO, and T _regs in the Melanoma Tumor Microenvironment Is Driven by CD8 ⁺ T Cells

2013 1.3k citations Stefani Spranger, Yuanyuan Zha et al. profile →
Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

2015 1.1k citations Thomas F. Gajewski et al. profile →
Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy

2017 1.1k citations Antoni Ribas, Igor Puzanov et al. profile →
Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy

2017 1.0k citations Stefani Spranger, Brendan Horton et al. profile →
Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment

2009 872 citations Helena Harlin, Yuru Meng et al. Cancer Research profile →
Helper T Cell Differentiation Is Controlled by the Cell Cycle

1998 733 citations Thomas F. Gajewski et al. profile →
Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones.

1988 725 citations Thomas F. Gajewski et al. The Journal of Immunology profile →
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

2019 703 citations Omid Hamid, Thomas F. Gajewski et al. profile →
PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells

2004 609 citations Christian U. Blank, Ian E. Brown et al. Cancer Research profile →
The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies

2018 528 citations Thomas F. Gajewski et al. Science profile →
Impact of oncogenic pathways on evasion of antitumour immune responses

2018 466 citations Stefani Spranger, Thomas F. Gajewski profile →
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

2014 456 citations Stefani Spranger, Brendan Horton et al. Journal for ImmunoTherapy of Cancer profile →
WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers

2019 454 citations Jason J. Luke, Riyue Bao et al. Clinical Cancer Research profile →
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors

2018 434 citations Jason J. Luke, Yuanyuan Zha et al. Journal of Clinical Oncology profile →
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

2016 391 citations F. Stephen Hodi, Thomas F. Gajewski et al. Journal for ImmunoTherapy of Cancer profile →
Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints

2015 380 citations Thomas F. Gajewski et al. profile →
STING pathway agonism as a cancer therapeutic

2019 259 citations Blake Flood, Emily F. Higgs et al. profile →
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy

2024 72 citations Thomas F. Gajewski et al. profile →

Peers

Countries citing papers authored by Thomas F. Gajewski

Since Specialization

Citations

This map shows the geographic impact of Thomas F. Gajewski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas F. Gajewski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas F. Gajewski more than expected).

Fields of papers citing papers by Thomas F. Gajewski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas F. Gajewski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas F. Gajewski. The network helps show where Thomas F. Gajewski may publish in the future.

Co-authorship network of co-authors of Thomas F. Gajewski

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas F. Gajewski. A scholar is included among the top collaborators of Thomas F. Gajewski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas F. Gajewski. Thomas F. Gajewski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeting molecular pathways to control immune checkpoint inhibitor toxicities 2024 ·Trends in Immunology ·Robin Reschke, Ryan J. Sullivan, Evan J. Lipson, Alexander Enk, Thomas F. Gajewski, Jessica C. Hassel	15
2	Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition 2023 ·European Journal of Cancer ·Robert Ferguson, (unknown), (unknown), Danny Simpson, (unknown), (unknown), (unknown), Gabriele Madonna, Mariaelena Capone, Ester Simeone, Anna C. Pavlick, Jason J. Luke, Thomas F. Gajewski, Iman Osman, Paolo A. Ascierto, Jeffrey S. Weber, Tomas Kirchhoff	6
3	Association Between Rheumatic Autoantibodies and Immune-Related Adverse Events 2023 ·The Oncologist ·(unknown), Sherin J. Rouhani, Daniel J. Olson, Anne R. Bass, Thomas F. Gajewski, Pankti Reid	12
4	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies 2022 ·Journal for ImmunoTherapy of Cancer ·Sherin J. Rouhani, Jovian Yu, Daniel J. Olson, Yuanyuan Zha, (unknown), Alexandra Cabanov, Athalia R. Pyzer, Jonathan Trujillo, Benjamin A. Derman, Peter H. O’Donnell, Andrzej Jakubowiak, Hedy L. Kindler, Christine M. Bestvina, Thomas F. Gajewski	8
5	Checkpoint Blockade–Induced Dermatitis and Colitis Are Dominated by Tissue-Resident Memory T Cells and Th1/Tc1 Cytokines 2022 ·Cancer Immunology Research ·Robin Reschke, Jason W. Shapiro, Jovian Yu, Sherin J. Rouhani, Daniel J. Olson, Yuanyuan Zha, Thomas F. Gajewski	62
6	Severe COVID-19 induces autoantibodies against angiotensin II that correlate with blood pressure dysregulation and disease severity 2022 ·Science Advances ·Priscilla S. Briquez, Sherin J. Rouhani, Jovian Yu, Athalia R. Pyzer, Jonathan Trujillo, Haley L. Dugan, Christopher T. Stamper, Siriruk Changrob, Anne I. Sperling, Patrick C. Wilson, Thomas F. Gajewski, Jeffrey A. Hubbell, Melody A. Swartz	31
7	Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma 2021 ·Journal of Clinical Oncology ·Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein, Andrew Poklepovic, Madhuri Bajaj, Sunil Babu, Sigrun Hallmeyer, Mario R. Velasco, Jose Lutzky, Emily F. Higgs, Riyue Bao, Timothy Carll, Brian Labadie, Thomas Krausz, Yuanyuan Zha, Theodore Karrison, Vernon K. Sondak, Thomas F. Gajewski, Nikhil I. Khushalani, Jason J. Luke	136
8	Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion 2020 ·Cancer Research ·Brian Koss, (unknown), Erin M. Taylor, Aaron J. Storey, Stephanie D. Byrum, Allen Gies, Charity L. Washam, Samrat Roy Choudhury, Jeong Hyun Ahn, Hidetaka Uryu, Jason B. Williams, Kimberly J. Krager, Tung-Chin Chiang, Samuel G. Mackintosh, Rick D. Edmondson, Nükhet Aykin‐Burns, Thomas F. Gajewski, Gang Greg Wang, Alan J. Tackett	25
9	Treatment with tocilizumab does not inhibit induction of anti-COVID-19 antibodies in patients with severe SARS-CoV-2 infection 2020 ·Clinical Cancer Research ·Alexandra Cabanov, Blake Flood, Jeffrey Bloodworth, Emily F. Higgs, Jessica Fessler, Michael Y.K. Leung, Kyle R. Cron, Jonathan Trujillo, Athalia R. Pyzer, Sherin J. Rouhani, Garth W. Strohbehn, Brian L. Heiss, Mark J. Ratain, Pankti Reid, Kiang-Teck J. Yeo, Randy F. Sweis, Yuanyuan Zha, Thomas F. Gajewski	0
10	WNT/β-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers breakdown → 2019 ·Clinical Cancer Research ·Jason J. Luke, Riyue Bao, Randy F. Sweis, Stefani Spranger, Thomas F. Gajewski	454
11	Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF -Mutant Melanoma 2019 ·Clinical Cancer Research ·Antoni Ribas, Adil Daud, Anna C. Pavlick, René González, Karl D. Lewis, Omid Hamid, Thomas F. Gajewski, Igor Puzanov, Matthew Wongchenko, Isabelle Rooney, Jessie J. Hsu, Yibing Yan, (unknown), Grant A. McArthur	30
12	High-Throughput Stability Screening of Neoantigen/HLA Complexes Improves Immunogenicity Predictions 2018 ·Cancer Immunology Research ·(unknown), Scott Anderson, (unknown), Marlies V. Hager, Yuanyuan Zha, Thomas F. Gajewski, David M. Kranz	35
13	Improving Efficacy and Safety of Agonistic Anti-CD40 Antibody Through Extracellular Matrix Affinity 2018 ·Molecular Cancer Therapeutics ·Jun Ishihara, (unknown), Lambert Potin, Peyman Hosseinchi, Kazuto Fukunaga, Martina Damo, Thomas F. Gajewski, Melody A. Swartz, Jeffrey A. Hubbell	36
14	Intratumoral CD8+ T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity 2017 ·Cancer Immunology Research ·Brendan Horton, Jason B. Williams, Alexandra Cabanov, Stefani Spranger, Thomas F. Gajewski	124
15	NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells 2016 ·The Journal of Immunology ·Ximena L. Raffo Iraolagoitia, Raúl G. Spallanzani, Nicolás I. Torres, Romina E. Araya, Andrea Ziblat, Carolina I. Domaica, Jessica Mariel Sierra, (unknown), (unknown), Thomas F. Gajewski, Norberto W. Zwirner, Mercedes B. Fuertes	86
16	Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy breakdown → 2015 ·Science ·Ayelet Sivan, Leticia Corrales, Nathaniel Hubert, Jason B. Williams, Keston Aquino-Michaels, Zachary M. Earley, (unknown), Yuk Man Lei, Bana Jabrì, Maria‐Luisa Alegre, Eugene B. Chang, Thomas F. Gajewski	2825
17	Phase II Study of Nilotinib in Melanoma Harboring KIT Alterations Following Progression to Prior KIT Inhibition 2015 ·Clinical Cancer Research ·Richard D. Carvajal, Donald P. Lawrence, Jeffrey S. Weber, Thomas F. Gajewski, René González, Jose Lutzky, Steven O’Day, Omid Hamid, Jedd D. Wolchok, Paul B. Chapman, Ryan J. Sullivan, Jerrold B. Teitcher, Nikhil H. Ramaiya, Anita Giobbie‐Hurder, Cristina R. Antonescu, Michael C. Heinrich, Boris C. Bastian, Christopher L. Corless, Jonathan A. Fletcher, F. Stephen Hodi	97
18	Phase I Studies of Sirolimus Alone or in Combination with Pharmacokinetic Modulators in Advanced Cancer Patients 2012 ·Clinical Cancer Research ·Ezra E.W. Cohen, Kehua Wu, Christine Hartford, Masha Kocherginsky, (unknown), Yuanyuan Zha, (unknown), Michael L. Maitland, (unknown), (unknown), Larry House, Jacqueline Ramı́rez, Samir D. Undevia, Gini F. Fleming, Thomas F. Gajewski, Mark J. Ratain	51
19	Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment breakdown → 2009 ·Cancer Research ·Helena Harlin, Yuru Meng, Amy Peterson, Yuanyuan Zha, Maria Tretiakova, Craig L. Slingluff, Mark D. McKee, Thomas F. Gajewski	872
20	Homeostatic Proliferation Plus Regulatory T-Cell Depletion Promotes Potent Rejection of B16 Melanoma 2008 ·Clinical Cancer Research ·Justin Kline, Ian E. Brown, (unknown), Christian U. Blank, John H. Strickler, (unknown), Long Zhang, Thomas F. Gajewski	79

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact